The clinicopathological analysis implied that furin inhibition in hepatoma tissues in which furin was over-expressed might result in worse prognosis in HCC patients and furin might not be a proper target for anti-liver cancer therapy. This evidence concerns the gene FURIN and hepatocellular carcinoma.